Simone Ribero1, Maria Rosaria Gualano2, Simona Osella-Abate3, Giacomo Scaioli2, Fabrizio Bert2, Martina Sanlorenzo4, Elena Balagna5, Maria Teresa Fierro4, Giuseppe Macripò5, Anna Sapino6, Roberta Siliquini2, Pietro Quaglino4. 1. Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy2Section of Dermatologic Surgery, Department of Oncology and Hematology, Città della Salute e della Scienza di Torino Hospital, Turin, Italy. 2. Department of Public Health, University of Turin, Turin, Italy. 3. Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy4Section of Surgical Pathology, Department of Medical Sciences, University of Turin, Turin, Italy. 4. Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy. 5. Section of Dermatologic Surgery, Department of Oncology and Hematology, Città della Salute e della Scienza di Torino Hospital, Turin, Italy. 6. Section of Surgical Pathology, Department of Medical Sciences, University of Turin, Turin, Italy.
Abstract
IMPORTANCE: The prognostic significance of regression in primary melanoma has been debated for many years. There is no consensus regarding the need for sentinel lymph node (SLN) biopsy when regression is present within the primary tumor. OBJECTIVE: To review the evidence that regression may affect SLN status. DATA SOURCES: A systematic review was performed by searching in MEDLINE, Scopus, and the Cochrane Library from January 1, 1990, through June 2014. STUDY SELECTION: All studies that reported an odds ratio (OR) or data on expected and observed cases of SLN positivity and histologic regression were included. DATA EXTRACTION AND SYNTHESIS: Primary random-effects meta-analyses were used to summarize ORs of SLN positivity and histologic regression. Heterogeneity was assessed using the χ2 test and I2 statistic. To assess the potential bias of small studies, we used funnel plots, the Begg rank correlation test, and the Egger weighted linear regression test. The methodologic quality of the studies was assessed according to the Strengthening of Reporting of Observational studies in Epidemiology (STROBE) checklist, and 2 different meta-analyses were performed based on those criteria. MAIN OUTCOMES AND MEASURES: Summary ORs of histologic regression of primary melanoma and SLN status. RESULTS: Of the 1509 citations found in the search, 94 articles were reviewed, and 14 studies comprising 10 098 patients were included in the analysis. In the combined 14 studies, patients with regression had a lower likelihood to have SLN positivity (OR, 0.56; 95% CI, 0.41-0.77) than patients without regression. On the basis of study quality, we found that patients with regression enrolled in high-quality studies had a lower likelihood to have SLN positivity (OR, 0.48; 95% CI, 0.32-0.72) compared with results of low-quality studies (OR, 0.73; 95% CI, 0.53-1.00). Examination of the funnel plot did not provide evidence of publication bias. CONCLUSIONS AND RELEVANCE: The results of this analysis showed that the risk of SLN positivity was significantly lower in patients with histologic regression compared with those without. Regression may be used in these cases to make a selection of which patients should be the most appropriate for this procedure.
IMPORTANCE: The prognostic significance of regression in primary melanoma has been debated for many years. There is no consensus regarding the need for sentinel lymph node (SLN) biopsy when regression is present within the primary tumor. OBJECTIVE: To review the evidence that regression may affect SLN status. DATA SOURCES: A systematic review was performed by searching in MEDLINE, Scopus, and the Cochrane Library from January 1, 1990, through June 2014. STUDY SELECTION: All studies that reported an odds ratio (OR) or data on expected and observed cases of SLN positivity and histologic regression were included. DATA EXTRACTION AND SYNTHESIS: Primary random-effects meta-analyses were used to summarize ORs of SLN positivity and histologic regression. Heterogeneity was assessed using the χ2 test and I2 statistic. To assess the potential bias of small studies, we used funnel plots, the Begg rank correlation test, and the Egger weighted linear regression test. The methodologic quality of the studies was assessed according to the Strengthening of Reporting of Observational studies in Epidemiology (STROBE) checklist, and 2 different meta-analyses were performed based on those criteria. MAIN OUTCOMES AND MEASURES: Summary ORs of histologic regression of primary melanoma and SLN status. RESULTS: Of the 1509 citations found in the search, 94 articles were reviewed, and 14 studies comprising 10 098 patients were included in the analysis. In the combined 14 studies, patients with regression had a lower likelihood to have SLN positivity (OR, 0.56; 95% CI, 0.41-0.77) than patients without regression. On the basis of study quality, we found that patients with regression enrolled in high-quality studies had a lower likelihood to have SLN positivity (OR, 0.48; 95% CI, 0.32-0.72) compared with results of low-quality studies (OR, 0.73; 95% CI, 0.53-1.00). Examination of the funnel plot did not provide evidence of publication bias. CONCLUSIONS AND RELEVANCE: The results of this analysis showed that the risk of SLN positivity was significantly lower in patients with histologic regression compared with those without. Regression may be used in these cases to make a selection of which patients should be the most appropriate for this procedure.
Authors: Bin Xu; Theresa Scognamiglio; Perry R Cohen; Manju L Prasad; Adnan Hasanovic; Robert Michael Tuttle; Nora Katabi; Ronald A Ghossein Journal: Hum Pathol Date: 2017-05-25 Impact factor: 3.466
Authors: Clio Dessinioti; Niki Dimou; Alan C Geller; Aravella Stergiopoulou; Serigne Lo; Ulrike Keim; Jeffrey E Gershenwald; Lauren E Haydu; Simone Ribero; Pietro Quaglino; Susana Puig; Josep Malvehy; Lidija Kandolf-Sekulovic; Tatjana Radevic; Roland Kaufmann; Laura Meister; Eduardo Nagore; Victor Traves; Grigorios G Champsas; Mihaela Plaka; Brigitte Dreno; Emilie Varey; David Moreno Ramirez; Reinhard Dummer; Joanna Mangana; Axel Hauschild; Friederike Egberts; Ketty Peris; Laura Del Regno; Ana-Maria Forsea; Sabina A Zurac; Ricardo Vieira; Ana Brinca; Iris Zalaudek; Teresa Deinlein; Eleni Linos; Evangelos Evangelou; John F Thompson; Richard A Scolyer; Claus Garbe; Alexander J Stratigos Journal: J Natl Cancer Inst Date: 2019-12-01 Impact factor: 13.506
Authors: Richard J B Walker; Nicole J Look Hong; Marc Moncrieff; Alexander C J van Akkooi; Evan Jost; Carolyn Nessim; Winan J van Houdt; Emma H A Stahlie; Chanhee Seo; May Lynn Quan; J Gregory McKinnon; Frances C Wright; Michail N Mavros Journal: Ann Surg Oncol Date: 2022-06-08 Impact factor: 4.339
Authors: Richard J Straker; Katharine Krupp; Cimarron E Sharon; Alexandra S Thaler; Nicholas J Kelly; Emily Y Chu; David E Elder; Xiaowei Xu; John T Miura; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2022-03-17 Impact factor: 4.339
Authors: Priyadharsini Nagarajan; Jin Piao; Jing Ning; Laura E Noordenbos; Jonathan L Curry; Carlos A Torres-Cabala; A Hafeez Diwan; Doina Ivan; Phyu P Aung; Merrick I Ross; Richard E Royal; Jennifer A Wargo; Wei-Lien Wang; Rashmi Samdani; Alexander J Lazar; Asif Rashid; Michael A Davies; Victor G Prieto; Jeffrey E Gershenwald; Michael T Tetzlaff Journal: Mod Pathol Date: 2019-08-05 Impact factor: 7.842